Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

SIMPLE SUMMARY: Assessment of measurable residual disease (MRD) identifies small numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment. The achievement of MRD negativity (no detectable AML cells remaining) typically predicts better outcomes for patients with AML. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Cluzeau, Thomas, Lemoli, Roberto M., McCloskey, James, Cooper, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909238/
https://www.ncbi.nlm.nih.gov/pubmed/35267586
http://dx.doi.org/10.3390/cancers14051278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909238/
https://www.ncbi.nlm.nih.gov/pubmed/35267586
http://dx.doi.org/10.3390/cancers14051278

Ejemplares similares